OR WAIT 15 SECS
Novo Nordisk announces that it will invest DKK1.5 billion (US$224 million) in a haemophilia treatment manufacturing facility in Denmark.
Novo Nordisk announced on May 4, 2015 that it would invest DKK1.5 billion (US$224 million) into a 7500-m2 facility in Kalundborg, Denmark. The manufacturing facility will be used specifically to produce APIs for NovoSeven and other products for haemophilia. NovoSeven RT (Coagulation Factor VIIa [Recombinany]) is used for the treatment and prevention of “bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions,” according to the product’s website.
"The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees," said Henrik Wulff, executive vice-president, product supply at Novo Nordisk, in a press release.
It is estimated that the facility will produce 100 new jobs in production and engineering, in addition to the 2800 people Novo Nordisk currently employs in Kalundborg. The facility is expected to be fully operational in 2020.
Source: Novo Nordisk